27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Platelets reduce anoikis and promote metastasis by activating YAP1 signaling

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Thrombocytosis is present in more than 30% of patients with solid malignancies and correlates with worsened patient survival. Tumor cell interaction with various cellular components of the tumor microenvironment including platelets is crucial for tumor growth and metastasis. Although it is known that platelets can infiltrate into tumor tissue, secrete pro-angiogenic and pro-tumorigenic factors and thereby increase tumor growth, the precise molecular interactions between platelets and metastatic cancer cells are not well understood. Here we demonstrate that platelets induce resistance to anoikis in vitro and are critical for metastasis in vivo. We further show that platelets activate RhoA-MYPT1-PP1-mediated YAP1 dephosphorylation and promote its nuclear translocation which induces a pro-survival gene expression signature and inhibits apoptosis. Reduction of YAP1 in cancer cells in vivo protects against thrombocytosis-induced increase in metastasis. Collectively, our results indicate that cancer cells depend on platelets to avoid anoikis and succeed in the metastatic process.

          Abstract

          Platelets have been associated with increased tumor growth and metastasis but the mechanistic details of this interaction are still unclear. Here the authors show that platelets improve anoikis resistance of cancer cells and increase metastasis by activating Yap through a RhoA/MYPT-PP1 pathway.

          Related collections

          Most cited references70

          • Record: found
          • Abstract: found
          • Article: not found

          Integrated Genomic Analyses of Ovarian Carcinoma

          Summary The Cancer Genome Atlas (TCGA) project has analyzed mRNA expression, miRNA expression, promoter methylation, and DNA copy number in 489 high-grade serous ovarian adenocarcinomas (HGS-OvCa) and the DNA sequences of exons from coding genes in 316 of these tumors. These results show that HGS-OvCa is characterized by TP53 mutations in almost all tumors (96%); low prevalence but statistically recurrent somatic mutations in 9 additional genes including NF1, BRCA1, BRCA2, RB1, and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three miRNA subtypes, four promoter methylation subtypes, a transcriptional signature associated with survival duration and shed new light on the impact on survival of tumors with BRCA1/2 and CCNE1 aberrations. Pathway analyses suggested that homologous recombination is defective in about half of tumors, and that Notch and FOXM1 signaling are involved in serous ovarian cancer pathophysiology.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The extracellular matrix at a glance.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              YAP/TAZ at the Roots of Cancer.

              YAP and TAZ are highly related transcriptional regulators pervasively activated in human malignancies. Recent work indicates that, remarkably, YAP/TAZ are essential for cancer initiation or growth of most solid tumors. Their activation induces cancer stem cell attributes, proliferation, chemoresistance, and metastasis. YAP/TAZ are sensors of the structural and mechanical features of the cell microenvironment. A number of cancer-associated extrinsic and intrinsic cues conspire to overrule the YAP-inhibiting microenvironment of normal tissues, including changes in mechanotransduction, inflammation, oncogenic signaling, and regulation of the Hippo pathway. Addiction to YAP/TAZ thus potentially represents a central cancer vulnerability that may be exploited therapeutically.
                Bookmark

                Author and article information

                Contributors
                vakharghan@mdanderson.org
                asood@mdanderson.org
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                21 August 2017
                21 August 2017
                2017
                : 8
                : 310
                Affiliations
                [1 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Department of Gynecologic Oncology and Reproductive Medicine, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77030 USA
                [2 ]ISNI 0000 0001 0679 2801, GRID grid.9018.0, Institute of Pathology, , Martin-Luther-University Halle-Wittenberg, ; Halle (Saale), Saxony-Anhalt 06112 Germany
                [3 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Department of Genomic Medicine, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77054 USA
                [4 ]Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Saxony-Anhalt, 06120 Germany
                [5 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Section of Benign Hematology, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77030 USA
                [6 ]ISNI 0000 0004 0445 0041, GRID grid.63368.38, Department of Systems Medicine and Bioengineering, , Houston Methodist Research Institute, Houston Methodist Hospital, ; Houston, TX 77030 USA
                [7 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Center for RNA Interference and Non-Coding RNA, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77054 USA
                [8 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Department of Experimental Therapeutics, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77054 USA
                [9 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Department of Systems Biology, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77054 USA
                [10 ]ISNI 0000 0000 9632 6718, GRID grid.19006.3e, Department of Obstetrics and Gynecology, , Cedars-Sinai Medical Center, Geffen School of Medicine at UCLA, ; Los Angeles, CA 90048 USA
                [11 ]ISNI 0000 0001 2109 4251, GRID grid.240324.3, Department of Gynecologic Oncology, , Laura and Isaac Perlmutter Cancer Centre, NYU Langone Medical Center, ; New York, NY 10016 USA
                [12 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Department of Pathology, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77030 USA
                [13 ]ISNI 0000 0001 2291 4776, GRID grid.240145.6, Department of Cancer Biology, , The University of Texas MD Anderson Cancer Center, ; Houston, TX 77054 USA
                Author information
                http://orcid.org/0000-0002-7880-7723
                http://orcid.org/0000-0002-4848-0168
                http://orcid.org/0000-0003-1038-8232
                Article
                411
                10.1038/s41467-017-00411-z
                5566477
                28827520
                010a8a40-cba7-4b9d-bcce-cd834df36925
                © The Author(s) 2017

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 November 2016
                : 27 June 2017
                Categories
                Article
                Custom metadata
                © The Author(s) 2017

                Uncategorized
                Uncategorized

                Comments

                Comment on this article